Prostate cancer diagnosis:: The impact on patients' mental health

被引:36
作者
Korfage, IJ
de Koning, HJ
Roobol, M
Schröder, FH
Essink-Bot, ML
机构
[1] Erasmus Univ, Med Ctr, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands
[2] Erasmus Univ, Med Ctr, Dept Urol, NL-3000 DR Rotterdam, Netherlands
关键词
prostatic neoplasms; quality of life; screening; PSA testing; diagnosis; mental health;
D O I
10.1016/j.ejca.2005.10.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Because the introduction of PSA testing has increased the reported incidence of prostate cancer, this study assessed the mental impact on men after receiving a diagnosis of prostate cancer. Participants in a prostate cancer screening trial (ERSPC) completed a questionnaire on health and, if diagnosed with prostate cancer, at two additional time points. In the pre-screening phase 3800 men (response 88%) completed the questionnaire. Of screen-diagnosed men (n = 82) 52 (response 63%) completed two additional assessments. Gleason scores were <= 7 in 96% of men. Mental and self-rated overall health worsened significantly immediately after diagnosis (P <= 0.04). Six months later these scores improved and no longer differed significantly from the pre-diagnosis score. After obtaining a pre-diagnosis assessment in prospective prostate cancer patients we found a significant negative mental impact of prostate cancer diagnosis based on PSA testing. We recommend that clinicians share their knowledge on the generally favourable prognosis with their patients. The methodological implication is that considering a post-diagnosis assessment as 'baseline' may lead to an underestimation of the patient's mental health. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:165 / 170
页数:6
相关论文
共 23 条
[1]  
*AM CANC SOC, 2004, CANC STAT PRES AM CA
[2]   Prostate cancer screening in the prostate, lung, colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the initial screening round of a randomized trial [J].
Andriole, GL ;
Levin, DL ;
Crawford, ED ;
Gelmann, ER ;
Pinsky, PF ;
Chia, D ;
Kramer, BS ;
Reding, D ;
Church, TR ;
Grubb, RL ;
Izmirlian, G ;
Ragard, LR ;
Clapp, JD ;
Prorok, PC ;
Gohagan, JK .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (06) :433-438
[3]   Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: Population-based estimates for the year 2000 by period analysis [J].
Brenner, H ;
Arndt, V .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (03) :441-447
[4]   EuroQol: The current state of play [J].
Brooks, R .
HEALTH POLICY, 1996, 37 (01) :53-72
[5]  
Cohen J., 1988, STAT POWER ANAL BEHA
[6]   Prostate cancer mortality reduction by screening:: Power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial [J].
de Koning, HJ ;
Liem, MK ;
Baan, CA ;
Boer, R ;
Schröder, FH ;
Alexander, FE .
INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (02) :268-273
[7]   Large-scale randomized prostate cancer screening trials:: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial [J].
de Koning, HJ ;
Auvinen, A ;
Sanchez, AB ;
da Silva, FC ;
Ciatto, S ;
Denis, L ;
Gohagan, JK ;
Hakama, M ;
Hugosson, J ;
Kranse, R ;
Nelen, V ;
Prorok, PC ;
Schröder, FH .
INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (02) :237-244
[8]   Lead times and overdetection due to prostate-specific antigen screening:: Estimates from the European randomized study of screening for prostate cancer [J].
Draisma, G ;
Boer, R ;
Otto, SJ ;
van der Cruijsen, IW ;
Damhuis, RAM ;
Schröder, FH ;
de Koning, HJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (12) :868-878
[9]  
Etzioni R, 2002, J NATL CANCER I, V94, P981
[10]   Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer [J].
Korfage, IJ ;
Essink-Bot, ML ;
Borsboom, GJJM ;
Madalinska, JB ;
Kirkels, WJ ;
Habbema, JDF ;
Schröder, FH ;
de Koning, HJ .
INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (02) :291-296